Bank of America downgraded Sun Pharma stock to ‘underperform’ from ‘neutral’, citing risks to premium valuations and slower speciality execution. The brokerage cut its target price, flagging concerns over Ilumya’s Medicare exposure, pricing pressures, and limited earnings visibility despite strong initial performance.
Aequs shares slide 6% after Q4 swings to loss despite strong revenue growth
Aequs Limited shares fell 6.25% after reporting a sharp decline in Q4FY26 profitability and widened full-year losses, despite robust revenue growth. Investors are concerned over
May 27, 2026